How genetic differences in immune-cell receptors change antibody medicine effects
Impacts of genetic variation in the Fc gamma receptor locus on functionality of natural killer cells and monocytes
This work looks at whether common genetic differences in Fc-gamma receptors change how antibody treatments work for people with autoimmune and related conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | North Carolina State University Raleigh NIH-funded |
| Lab location | 1 site (Raleigh, United States) |
| Project ID | NIH-11248740 on NIH RePORTER |
What this research studies
From a patient's viewpoint, researchers are mapping genetic differences in Fc-gamma receptors and testing how those differences change the behavior of natural killer cells and monocytes. They use a high-throughput lab assay to screen many single nucleotide variants and copy-number differences in the Fc-gamma receptor region. The team then measures how those genetic changes alter antibody-dependent killing and phagocytosis in immune cells, using human-derived samples and experimental models. The goal is to link specific genetic patterns to weaker or stronger responses to antibody therapies.
Who could benefit from this research
Good fit: Ideal participants would be people with autoimmune diseases (or others receiving antibody treatments) who can provide blood samples for genetic and immune testing.
Not a fit: People whose conditions are not treated with antibody-based drugs or who cannot provide blood samples are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, this could help predict who is likely to respond well to antibody therapies and guide more personalized treatment choices.
How similar studies have performed: Previous studies have linked some Fc-gamma receptor variants to different responses to antibody therapies, but the receptor locus is highly complex and comprehensive functional data remain limited.
Where this research is happening
Raleigh, United States
- North Carolina State University Raleigh — Raleigh, United States (Active)
Researchers
- Principal investigator: Peng, Xinxia — North Carolina State University Raleigh
- Study coordinator: Peng, Xinxia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.